Vidyya Medical News Service
*
Volume 6 Issue 231 Published - 14:00 UTC 08:00 EST 18-Aug-2004 Next Update - 14:00 UTC 08:00 EST 19-Aug-2004
little clear gif used for spacer
 
 

Clinical trial information: Treatment of Adolescent Suicide Attempters (TASA)

This study is currently recruiting patients.

Purpose

The purpose of this study is to compare the effects of three types of treatments for depressed teenagers who have attempted suicide.

Condition Treatment or Intervention Phase
Major Depressive Disorder
Depressive Disorder not otherwise specified (NOS)
Dysthymic Disorder
 Drug: fluoxetine
 Drug: sertraline
 Drug: citalopram
 Drug: escitalopram
 Drug: buproprion
 Drug: mirtazapine
 Drug: venlafaxine
 Drug: lithium
 Behavior: Cognitive Behavioral Therapy
Phase II
Phase III

MedlinePlus related topics:  Mental Health

Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study

Further Study Details: 

Suicide is the third leading cause of death in adolescents and is a major public health problem. Depression is the most common diagnosis for adolescent suicide attempts. Little is known about what treatment is best for these adolescents since they are usually excluded from participation in research studies.

Participants in this study will be randomly assigned to receive carefully monitored antidepressant medication with routine support and management, cognitive behavioral therapy (CBT), or a combination of antidepressant medication plus CBT.

Eligibility

Ages Eligible for Study:  12 Years   -   18 Years,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

  • At least one suicide attempt or interrupted attempt within the past 45 days
  • Continuously reside with a primary caretaker (parent, legal guardian, foster parent) for at least 6 months that can provide legal consent

Expected Total Enrollment:  120

Location and Contact Information

Ben Vitiello, MD      301.443.4283    bvitiell@mail.nih.gov

Maryland
      Johns Hopkins University, Baltimore,  Maryland,  21287,  United States; Recruiting
Deidre Everist  410-955-7675    deverist@jhmi.edu 
John Walkup, MD,  Principal Investigator

New York
      Columbia University at the New York State Psychiatric Institute, New York,  New York,  10032,  United States; Recruiting
Lisa Capasso  212-543-6039    capassol@childpsych.columbia.edu 
Laurence Greenhill, MD  212.543.5340    greenhill@childpsych.columbia.edu 
Laurence Greenhill, MD,  Principal Investigator

      New York University Child Study Center, New York,  New York,  10016,  United States; Recruiting
Lori Evans, PhD  212-263-3661    lori.evans@med.nyu.edu 
Angela Chiu  212.263.3651    chiua02@med.nyu.edu 
Barbara Coffey, MD,  Principal Investigator

North Carolina
      Duke University Medical Center, Durham,  North Carolina,  27705,  United States; Recruiting
Scott Compton, PhD  919-416-2416    scompton@duke.edu 
Denny Hood  919.416.2410    hood0010@mc.duke.edu 
Karen Wells, PhD,  Principal Investigator

Pennsylvania
      University of Pittsburgh - Western Psychiatric Institute and Clinic, Pittsburgh,  Pennsylvania,  15213,  United States; Recruiting
Jamie Zelazny, RN  412-246-6124    zelaznyjh@msx.upmc.edu 
David Brent, MD,  Principal Investigator

Texas
      University of Texas, Southwestern Medical Center, Dallas,  Texas,  75235,  United States; Recruiting
Jenny Hughes  214-648-4397    jennifer.hughes@utsouthwestern.edu 
Graham Emslie, MD,  Principal Investigator

Study chairs or principal investigators

Laurence Greenhill, MD,  Study Chair

More Information

Study ID Numbers  1U10MH66762-01
Study Start Date March 2004
Record last reviewed  June 2004
NLM Identifier  NCT00080158
ClinicalTrials.gov processed this record on 2004-08-17

Additional Vidyya Resources:


© Vidyya.
 
 

  More Today in Vidyya